Moleculin enrolls 45th patient in Phase 2B/3 MIRACLE trial of Annamycin combo for relapsed AML

Moleculin Biotech, Inc.

Moleculin Biotech, Inc.

MBRX

0.00
  • Moleculin Biotech reached 45 enrollments in its pivotal Phase 2B/3 MIRACLE trial of AnnAraC for relapsed or refractory acute myeloid leukemia.
  • The milestone triggers final preparations for an interim data unblinding, with results expected in mid-2026.
  • The readout is positioned as a key inflection point that could shape the program’s regulatory path and near-term strategy.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Moleculin Biotech Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202606040831PRIMZONEFULLFEED9731843) on June 04, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.